Glenmark Pharmaceuticals launches Bumex Injection generic in US

TAGS

Glenmark Pharmaceuticals said that its US-based subsidiary has launched Bumetanide Injection USP, 1 mg/4 mL (0.25 mg/mL) SingleDose Vials and 2.5 mg/10 mL (0.25 mg/mL) Multi-Dose Vials.

The launched product is the generic version of ‘ Bumex Injection, 0.25 mg/mL.

Bumex is indicated for the treatment of swelling and .

As per IQVIA sales data for the 12 months ending November 2022, the Bumex Injection, 0.25 mg/mL market had annual sales of around $16.5 million.

See also  Nassau Life Insurance expands portfolio with acquisition of DLNY

— Glenmark Pharmaceuticals Senior Vice President, Business Development Portfolio, Product Launch & Strategy said: “We are very pleased to bring to market a lower cost alternative to Bumex Injection, 0.25 mg/mL.

“This launch of Bumetanide Injection USP, 1 mg/4 mL (0.25 mg/mL) Single-Dose Vials and 2.5 mg/10 mL (0.25 mg/mL) Multi-Dose Vials affirms our commitment to Glenmark’s continued focus on institutional business.”

See also  Google amplifies AI security with Anthropic's Cloud TPU v5e adoption

The current portfolio of Glenmark Pharmaceuticals features 179 products with (FDA) authorization for distribution in the US marketplace and 46 abbreviated new drug applications (ANDAs) awaiting approval from the regulator.


Discover more from Business-News-Today.com

Subscribe to get the latest posts sent to your email.

CATEGORIES
TAGS
Share This